Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2004

01-09-2004 | Authors’ Reply

Reply to Comment on: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 43:31–39

Authors: A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, R. A. DeFronzo

Published in: Diabetologia | Issue 9/2004

Login to get access

Excerpt

To the Editor: Dr Jenkins and colleagues raise two issues. The first relates to the validity of the strong inverse relationship between disposition indices and plasma glucose concentrations. The second relates to the effects of obesity on indices of beta cell function. They state that our conclusion appears inconsistent with their finding that “baseline adiposity predicts reduced beta cell function at 6-year follow up, and does so independently of diabetes risk status.” They also state that our findings “are based on spurious correlations.” We offer the following comments. …
Literature
1.
Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47:31–39CrossRefPubMed
2.
Ferrannini E, Mari A (2004) Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 47:943–956CrossRefPubMed
3.
Kriketos AD, Carey DG, Jenkins AB, Chisholm DJ, Furler SM, Campbell LV (2003) Central fat predicts deterioration of insulin secretion and fasting glycemia: 6-year follow-up of subjects at varying risk of Type 2 diabetes mellitus. Diabetic Med 20:294–300PubMed
Metadata
Title
Reply to Comment on: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 43:31–39
Authors
A. Gastaldelli
E. Ferrannini
Y. Miyazaki
M. Matsuda
R. A. DeFronzo
Publication date
01-09-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1479-3

Other articles of this Issue 9/2004

Diabetologia 9/2004 Go to the issue

Article

Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients

Article

Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms

Article

Metabolic adaptations to chronic glucose infusion in rats

Article

Albumin excretion in diabetic patients in the setting of acute myocardial infarction: association with 3-year mortality

Book reviews

R. Hanas (2002) Type 1 Diabetes in children, adolescents and young adults. How to become an expert on your own diabetes. Second edition. Class Publishing, London, UK. (ISBN 1 85959 078 0)

Article

Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits